We report the case of a 50-year-old female renal transplant patient who developed disseminated deposits initially diagnosed as metastatic malignancy of unknown primary. She declined a tissue diagnosis but subsequently developed recurrent sepsis and symptomatic unilateral pleural effusion. Mycobacterium tuberculosis was cultured from pleural fluid. Following introduction of anti-tuberculous medications, her symptoms improved rapidly and the progression of her disseminated deposits stabilized. Tuberculosis is well-known to be associated with immunocompromised patients. It is a curable disease and should remain an important differential diagnosis for transplant patients who develop suspicious malignant metastatic lesions.
INTRODUCTION
Patients who receive solid organ transplantation are at risk of both malignancies and atypical infections such as Tuberculosis (TB) [1] . Both are life threatening, but TB is a curable communicable disease. It is important to note that TB and malignancy can have overlapping symptoms and signs. We present a case study of a renal transplant patient who developed disseminated lesions initially thought to be metastatic malignancy of unknown primary, but later developed miliary TB which improved with treatment.
CASE REPORT
A 50-year-old female of Filipino heritage received a living unrelated renal transplant in August 2013. Her past history included end-stage renal failure of unknown aetiology, hypertension, transient ischaemic attack and cervical cancer treated with transabdominal hysterectomy and radiotherapy. Post-transplant immunosuppression consisted of Prednisolone and trough level controlled Tacrolimus. Post-operatively she developed multiple complications including recurrent ureteric obstruction and failed ureteric stents necessitating long-term nephrostomy. She suffered from recurrent urinary tract infections caused by multiresistant Escherichia coli and Pseudomonas sp. Despite the above, her transplant functioned well with a baseline Creatinine of 140 µmol/L and estimated glomerular filtration rate of 34 mL/min/ 1.73 m 2 . Following risk assessment, TB prophylaxis was considered but not prescribed due to her multiple complications and illnesses in the immediate post-transplant period.
In October 2014 she was admitted with abdominal and back pain. A computed-tomography (CT) revealed new lytic lesions in multiple vertebral bodies and iliac bones, confirmed on magnetic resonance imaging (MRI) (Fig. 1) . Following a negative myeloma screen, she was given a provisional diagnosis of metastatic malignancy of unknown primary. The patient declined a tissue diagnosis at that time and opted for palliative management of her symptoms. She received a course of palliative radiotherapy for impending cord compression and for pain control. She had several admissions in rapid succession with fever and rigors which were thought to be due to sepsis that resolved quickly with intravenous antibiotic administration. Pain control was always worse during these episodes, but sites of reported pain did not fit with her known spinal lesions.
In November 2015, the patient was admitted with chest pain and breathlessness. CT scan revealed progression of her bony lesions with bilateral pulmonary nodules, pleural thickening and new unilateral pleural effusion initially thought to be lung malignancy (Fig. 2) . The effusion was drained twice for symptomatic relief. Pleural fluid analysis revealed an exudate with LDH of 525 U/L and protein 38 g/L. Cytology was negative but Acid-Fast Bacilli were grown from TB culture 3 weeks later, subsequently confirmed to be Mycobacterium tuberculosis.
She was treated with Rifampicin, Isoniazid, Pyrazinamide and Ethambutol, with the latter 2 discontinued 2 months later. Following 2 months introduction of anti-tuberculous therapy, her pulmonary nodules and pleural effusion resolved completely (Fig. 3) . Bone biopsy to conclusively rule out malignancy was offered but declined by the patient. Subsequent follow-up MRIs showed significant improvement of her spinal lesions.
DISCUSSION
TB is one of the most important causes of premature death worldwide, killing 1.5 million people every year [2] . The overall incidence of TB in the UK has remained stable in the past decade, but a significant proportion of cases are reported in large urban cities (e.g. London, Birmingham) [3] . Overall, 75% of TB cases in the UK occur in patients born overseas, particularly those born in countries with high TB risk [3] . Other risk factors include HIV infection, alcohol excess, chronic renal disease, haemodialysis and patients receiving immunosuppression therapy-particularly those who have received solid organ transplantation [4] . The risk of TB infection in transplant patients is at least 30 times higher than that of the general population [5] . Most UK centres routinely offer prophylactic anti-tuberculous therapy for transplant patients at higher risk of developing TB.
Transplant patients also have an overall 2-fold increase in incidence of malignancies-these can be malignancies driven by oncogenic viral infections (e.g. lymphoma, anorectal and cervical cancers), or non-infection related (e.g. skin, lung, liver and thyroid cancers) [6] . Patients receiving organ transplantation are therefore routinely counselled regarding the risk of cancer. The classical symptoms of productive cough and haemoptysis in TB may not always be present in immunosuppressed patients. Patients may have non-specific symptoms such as recurrent fever, lethargy, chest pain and weight loss. Miliary TB, in particular, may have overlapping clinical and radiological features with metastatic malignancy. Due to the relative rarity of TB among patients in the UK, it is therefore unsurprising that we often do not routinely consider TB as part of our differential diagnosis.
Treatment of TB in transplant patients require close liaison between Transplant specialists and Respiratory or Infectious Diseases specialists. Routine treatment in the UK will include 2 months of quadruple therapy (Rifampicin, Isoniazid, Ethambutol and Pyrazinamide), followed by at least 4 further months of dual therapy (Rifampicin and Isoniazid). It is crucial to note that Rifampicin is a potent inducer of the hepatic CYP450 enzyme system, therefore the dosages of corticosteroids and calcineurin inhibitors, both commonly used in transplant recipients, need to be dose-adjusted accordingly.
CONCLUSION
Patients who have received solid organ transplantation are at risk of both malignancies and atypical infections including TB, which can present in an unusual manner. TB is a curable disease, and should remain an important differential diagnosis in immunosuppressed patients who develop suspicious metastatic lesions. liaison between transplant and TB specialists due to interactions between anti-tuberculous and immunosuppression therapy.
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